Dementia with Lewy Bodies

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer disease, yet two of every three cases are missed or misdiagnosed — with an average 18-month delay to correct diagnosis. This diagnostic gap has profound consequences: patients exposed to typical antipsychotics may develop severe or fatal neuroleptic sensitivity reactions, and families miss the window for appropriate support and planning. DLB, together with Parkinson disease dementia (PDD), falls under the umbrella of Lewy body dementia (LBD), with both conditions sharing the pathology of neuronal α-synuclein aggregation (Lewy bodies and Lewy neurites). The clinical distinction is the 1-year rule: if dementia occurs before or within 1 year of motor symptoms, the diagnosis is DLB; if dementia develops after 1 year of established PD, it is PDD. While this convention facilitates clinical classification, DLB and PDD likely represent a continuum with variable cortical and subcortical involvement.

Clinical Features and Recognition

Cognitive Profile

The cognitive signature of DLB differs fundamentally from Alzheimer disease. Patients with DLB experience prominent early executive dysfunction (difficulty problem-solving, multitasking, planning, organizing), attentional deficits (losing the train of thought, inability to follow plots or conversations, easy distractibility), and visuospatial impairment (difficulty with spatial navigation including getting lost in their own home, trouble recognizing objects, parking difficulties, driving too close to others). Episodic memory is relatively preserved early — a key differentiator from the amnestic pattern of Alzheimer disease, though copathology with AD may blur this distinction.

Cognitive fluctuations are highly characteristic and often underappreciated. Care partners describe days when the patient functions well, followed by periods of confusion, blank staring, and inability to complete routine tasks. These fluctuations in attention and alertness distinguish DLB from the more gradual, consistent decline of Alzheimer disease. No pharmacologic treatment reliably improves fluctuations, though cholinesterase inhibitors are sometimes tried.

Visual Hallucinations and Psychosis

Recurrent, well-formed visual hallucinations occur in up to 80% of patients with DLB and are often among the earliest symptoms. Hallucinations typically involve people (familiar or unfamiliar, living or deceased), children, or animals. Additional psychotic phenomena include passage hallucinations (shadows perceived in peripheral vision), visual illusions (a garden hose interpreted as a snake), presence hallucinations (feeling someone is nearby), and Capgras syndrome (delusion that a familiar person has been replaced by an identical imposter). The degree of insight varies, and treatment is only necessary when hallucinations cause distress or safety concerns.

REM Sleep Behavior Disorder

RBD — dream enactment with vocalizations and motor activity during REM sleep — is a core feature that may precede cognitive decline by years or decades. Care partners report the patient yelling, punching, flailing, or jumping out of bed during sleep. Polysomnographic confirmation of REM sleep without atonia is an indicative biomarker for DLB. RBD is also common in PD and MSA but is rare in PSP and Alzheimer disease — making it a useful differential diagnostic feature.

Parkinsonism

Motor features include bradykinesia, rigidity, and resting tremor — though parkinsonism in DLB tends to be more symmetric or axial-predominant compared with the characteristically asymmetric presentation of PD. Motor response to levodopa is typically less robust than in PD. Other motor features include postural instability, repeated falls, and hypomimia.

Supportive Features

Severe antipsychotic sensitivity is a hallmark of DLB. Exposure to typical antipsychotics (haloperidol, chlorpromazine) or even some atypical agents (risperidone, olanzapine) can cause profound worsening of parkinsonism, sedation, immobility, neuroleptic malignant syndrome–like reactions, and death in up to one-third of exposed patients. Other supportive features include hypersomnia, hyposmia, postural instability, repeated falls, apathy, anxiety, depression, and hallucinations in non-visual modalities.

Diagnostic Criteria

2017 Fourth Consensus Criteria

Prodromal DLB

Three prodromal syndromes enable earlier recognition:

(1) MCI with Lewy bodies: Attention, executive, and visuospatial deficits without functional impairment — the cognitive changes mirror DLB but do not meet dementia criteria. Probable MCI-LB requires ≥2 core features or 1 core + ≥1 proposed biomarker. Possible MCI-LB requires 1 core feature alone or ≥1 biomarker alone.

(2) Delirium-onset DLB: Delirium occurring before dementia onset. Delirium occurs more frequently in individuals later diagnosed with DLB than AD. This presentation may be triggered by hospitalization, surgery, infection, or medication changes and should prompt evaluation for underlying Lewy body pathology.

(3) Psychiatric-onset DLB: Late-onset major depressive disorder or late-onset psychosis (including hallucinations, systematized delusions, Capgras syndrome) preceding cognitive decline. Core DLB features may have limited diagnostic value in this context because fluctuations are poorly characterized, cognitive changes may be masked by psychiatric symptoms, RBD may be attributed to antidepressants, and parkinsonism may be attributed to antipsychotics.

Biomarkers and Diagnostic Tools

Imaging

Structural MRI: Shows generalized cortical atrophy in a nonspecific pattern with relative preservation of the medial temporal lobes — unlike Alzheimer disease, where hippocampal atrophy is prominent. Note that AD copathology may produce medial temporal atrophy even in DLB.

Dopamine transporter (DaT) imaging: FDA-approved for DLB. Sensitivity 80%, specificity 92% for distinguishing DLB from AD (autopsy-validated). Most helpful for the DLB-vs-AD question. However, reduced DaT uptake occurs across all degenerative parkinsonisms (PD, MSA, PSP, CBS, some FTDs) — it does not differentiate DLB from other parkinsonian conditions.

FDG-PET: Occipital hypometabolism with relative preservation of the posterior cingulate — the cingulate island sign. This pattern distinguishes DLB from AD (where posterior cingulate hypometabolism is typical). Approximately 90% sensitivity for DLB.

Cardiac MIBG scintigraphy: Reduced cardiac sympathetic innervation in DLB (sensitivity 69%, specificity 87% vs AD for probable DLB; sensitivity 59%, specificity 88% for MCI-LB vs MCI-AD). Not available in many countries including the US.

α-Synuclein Biomarkers

CSF α-synuclein SAA: Detects pathologic α-synuclein across the Lewy body spectrum with sensitivity 59–95% and specificity 83–98%. Sensitivity varies by pathologic distribution: neocortical (97–100%), limbic (96%), amygdala-predominant (43–50%), brainstem-predominant (17–50%). Critically, SAA is typically negative in MSA (glial not neuronal α-synuclein) — invaluable for differentiating DLB from MSA when overlap exists. No reliable plasma SAA exists yet. Genetic variants (GBA, LRRK2) may alter SAA kinetics.

Skin biopsy: Detects phosphorylated α-synuclein in cutaneous nerve fibers with >92% sensitivity for synucleinopathies. Three punch biopsies (posterior cervical, posterior thigh, posterior distal leg) are performed. In DLB/PD, deposits localize predominantly to autonomic fibers at proximal sites, whereas in MSA they appear in somatosensory fiber terminals at distal sites.

Other Diagnostic Tools

Polysomnography: Confirmation of REM sleep without atonia is an indicative biomarker. Essential in patients with reported dream enactment behavior, particularly to differentiate from obstructive sleep apnea, nocturnal seizures, or non-REM parasomnias.

Quantitative EEG: Posterior slow-wave activity (<8 Hz) is a supportive biomarker for DLB, observed in ~90% of DLB patients vs ~10% of AD patients.

Neuropsychological assessment: MoCA is a useful screening tool that captures executive, attentional, and visuospatial deficits. Detailed neuropsychological testing should include trail-making tests, Stroop task, phonemic fluency, Wisconsin Card Sorting Test (executive/attention), and figure copy, line orientation, and pareidolia tests (visuospatial).

Copathology and Genetics

Copathology is the rule rather than the exception in DLB. Alzheimer disease pathology (amyloid-beta plaques and neurofibrillary tangles) is present in at least 50% of DLB cases and is clinically associated with greater cognitive decline, higher rates of institutionalization, and increased mortality. Other copathologies include TDP-43, cerebrovascular disease, and additional tau. The presence and severity of copathology substantially influences clinical phenotype and prognosis, making each DLB patient's trajectory somewhat unique.

Most DLB is sporadic, but genetic factors play a role. Identified risk variants include GBA1 (strongest genetic risk factor, shared with PD), APOE ε4 (shared with AD), SNCA, BIN1, TMEM175, TPCN1, and SCARB2. The genetic overlap with both PD and AD reflects DLB's position at the intersection of synucleinopathy and amyloidopathy.

Management

No disease-modifying therapies exist. Management requires an interdisciplinary team — neurology, psychiatry, cardiology, urology, palliative care, and rehabilitation specialists. The fundamental principle is to ask the patient and care partner which symptoms to prioritize, then systematically address them while avoiding iatrogenic harm.

Symptom-by-Symptom Management

Amyloid Copathology and Anti-Amyloid Therapy

With FDA-approved anti-amyloid therapies for early Alzheimer disease (lecanemab, donanemab), the question arises: should DLB patients with amyloid positivity be treated? Currently, DLB is outside the appropriate use criteria. No trials address this question, and several concerns remain — including the risk of ARIA (amyloid-related imaging abnormalities) in patients with possible cerebral amyloid angiopathy, and whether reducing amyloid burden meaningfully improves outcomes in a disease driven primarily by α-synuclein. Nonetheless, there is developing momentum to explore this overlap in future trials.

Health Disparities

DLB remains profoundly underdiagnosed across demographic groups. One study found that 50% of patients were evaluated by >3 doctors for >10 visits over 1 year before receiving an LBD diagnosis. Access to specialty care is significantly lower for Asian, Black, and Hispanic individuals. Only 15% of Black/African American participants in the National Alzheimer's Coordinating Center received a clinical DLB diagnosis, compared with 30.4% of White participants — despite 70% of Black/African American participants having Lewy body pathology at autopsy. Women with DLB frequently experience delayed diagnosis, possibly due to milder parkinsonism, lower RBD rates, and later emergence of core features. Since 62% of DLB diagnoses are made by neurologists (vs 6% by primary care), limited neurology access amplifies these disparities.

Disease Progression and Prognosis

DLB progresses faster than Alzheimer disease, with estimated survival of 5–8 years from symptom onset. In a caregiver interview study, the most common causes of death were: failure to thrive (65%), pneumonia and swallowing difficulties (23%), other medical conditions (19%), and complications from falls (10%). Early referral to palliative care and hospice services is essential, along with timely discussions of advance care planning, driving safety, and home safety.

Trial Comparison Table

References

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
2. McKeith IG, Ferman TJ, Thomas AJ, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743-755.
3. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease (EXPRESS). N Engl J Med. 2004;351(24):2509-2518.
4. Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis (HARMONY). N Engl J Med. 2021;385(4):309-319.
5. Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178-190.
6. Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. JAMA. 2024;331(15):1298-1306.
7. Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the PPMI cohort using α-synuclein seed amplification. Lancet Neurol. 2023;22(5):407-417.
8. Armstrong MJ, McFarland NR. Dementia with Lewy bodies. Continuum (Minneap Minn). 2025;31(4):956-978.